
    
      Study S187.3.003 (NCT00360568) is a Phase 3, 12-month, open-label, multicenter continuation
      treatment study of the safety, tolerability, and efficacy of levodopa-carbidopa intestinal
      gel (LCIG) in the treatment of participants with levodopa-responsive Parkinson's disease (PD)
      with persistent motor fluctuations despite optimized treatment with available PD medications.
      All participants received LCIG.

      Only participants who completed 12 weeks of double-blind, double-dummy treatment in Study
      S187.3.001 or S187.3.002 (NCT00357994/ NCT00660387) qualified for enrollment in this 12-month
      continuation treatment study.
    
  